• How can pre-trial screening effectively predict side effects and symptoms associated with reproductive therapeutics.
• What are the appropriate safety profiles to apply for endometriosis, PCOS, and fibroids.

• Exploring the current landscape of screening services in women’s cancers and market opportunities to address unmet need.

• Sharing how AI, technology, and genetic testing can address gaps in access.

• How providers and patients can be equipped with tools for early detection and cancer prevention.

• How the demand for menopause-focused functional foods, probiotics, and supplements is shaping new business opportunities.
• Sharing insights into how nutrition and food as medicine links bone, heart, and brain health in menopause and the opportunity to address these health outcomes through wellness.
• Expanding access to menopause nutrition solutions through pharmacies, e-commerce, consumer wellness, and employer plans.

Demonstrate how AI-driven initiatives - like predictive modelling and automated inspection -translate into measurable outcomes (e.g., defect reduction, shorter batch release cycles) that justify capital investment and cross-functional prioritization

• Leveraging tech and epidemiological data to reduce diagnostic delays in reproductive health.
• Exploring AI, biomarkers, digital therapeutics, and digital platforms that enable earlier and more accurate diagnoses.
• Advice to start-ups and sharing the market opportunity for clinical integration in preventative & diagnostic women’s health.

• Discussing the emerging trends of women’s health education & awareness on social media.
• How companies can best utilize social media for marketing & business opportunity.
• Addressing misinformation, trust and health literacy impacting health & wellness decision-making.